[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @JohnCendpts John Carroll John Carroll posts on X about $gsk, ipo, $xbi, $bmy the most. They currently have XXXXXX followers and X posts still getting attention that total XX engagements in the last XX hours. ### Engagements: XX [#](/creator/twitter::102754598/interactions)  - X Week XXXXXX +389% - X Month XXXXXX +111% - X Months XXXXXXX +124% - X Year XXXXXXX -XX% ### Mentions: X [#](/creator/twitter::102754598/posts_active)  - X Week X +25% - X Month XX -XX% - X Months XX -XX% - X Year XXX +67% ### Followers: XXXXXX [#](/creator/twitter::102754598/followers)  - X Week XXXXXX +0.07% - X Month XXXXXX +0.20% - X Months XXXXXX +1% - X Year XXXXXX -XXXX% ### CreatorRank: undefined [#](/creator/twitter::102754598/influencer_rank)  ### Social Influence [#](/creator/twitter::102754598/influence) --- **Social category influence** [stocks](/list/stocks) XX% [finance](/list/finance) XX% [technology brands](/list/technology-brands) XXXX% **Social topic influence** [$gsk](/topic/$gsk) 12.5%, [ipo](/topic/ipo) 12.5%, [$xbi](/topic/$xbi) 12.5%, [$bmy](/topic/$bmy) 12.5%, [$15b](/topic/$15b) 12.5%, [vivo](/topic/vivo) 12.5%, [acquisition](/topic/acquisition) XXXX% **Top accounts mentioned or mentioned by** [@biotech](/creator/undefined) [@bambossie81](/creator/undefined) [@pharma](/creator/undefined) [@kylahucik](/creator/undefined) [@chrisdoko](/creator/undefined) [@nicole_paulk](/creator/undefined) [@jasonford6](/creator/undefined) [@biotec1000](/creator/undefined) **Top assets mentioned** [GSK plc (GSK)](/topic/$gsk) [Bitcoin Incognito (XBI)](/topic/$xbi) [Bristol-Myers Squibb Co (BMY)](/topic/$bmy) ### Top Social Posts [#](/creator/twitter::102754598/posts) --- Top posts by engagements in the last XX hours "$GSK is up a bit this morning on the news that Emma Walmsley is leaving handing the top job to commercial chief Luke Miels. Essentially the stock is priced exactly what it was when she got the job in April 2017. The numbers are still in question. Investors wonder where the big products will head from here after Shingrix initially gave it a boost. The pipeline is still in doubt. But of course the PR was full of triumphalism about its longterm growth. Disappointing" [X Link](https://x.com/JohnCendpts/status/1972647061070749748) [@JohnCendpts](/creator/x/JohnCendpts) 2025-09-29T12:58Z 70.7K followers, 5976 engagements "Some key metrics in biotech showed some strengthening in Q3. And while a single modestly successful IPO doesn't make a trend an improving $XBI and a focus on deals makes me wonder if the worst is over in biotech. I certainly hope so" [X Link](https://x.com/JohnCendpts/status/1977702109387665565) [@JohnCendpts](/creator/x/JohnCendpts) 2025-10-13T11:45Z 70.7K followers, 4939 engagements "Thumbs up to Kristina Burow and the other backers of Orbital as $BMY steps in with a $1.5B buyout. In vivo is where it's at right now. Ryan Cross featured Orbital in the 2023 Endpoints 11" [X Link](https://x.com/JohnCendpts/status/1976642137518477337) [@JohnCendpts](/creator/x/JohnCendpts) 2025-10-10T13:33Z 70.7K followers, 2391 engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
John Carroll posts on X about $gsk, ipo, $xbi, $bmy the most. They currently have XXXXXX followers and X posts still getting attention that total XX engagements in the last XX hours.
Social category influence stocks XX% finance XX% technology brands XXXX%
Social topic influence $gsk 12.5%, ipo 12.5%, $xbi 12.5%, $bmy 12.5%, $15b 12.5%, vivo 12.5%, acquisition XXXX%
Top accounts mentioned or mentioned by @biotech @bambossie81 @pharma @kylahucik @chrisdoko @nicole_paulk @jasonford6 @biotec1000
Top assets mentioned GSK plc (GSK) Bitcoin Incognito (XBI) Bristol-Myers Squibb Co (BMY)
Top posts by engagements in the last XX hours
"$GSK is up a bit this morning on the news that Emma Walmsley is leaving handing the top job to commercial chief Luke Miels. Essentially the stock is priced exactly what it was when she got the job in April 2017. The numbers are still in question. Investors wonder where the big products will head from here after Shingrix initially gave it a boost. The pipeline is still in doubt. But of course the PR was full of triumphalism about its longterm growth. Disappointing"
X Link @JohnCendpts 2025-09-29T12:58Z 70.7K followers, 5976 engagements
"Some key metrics in biotech showed some strengthening in Q3. And while a single modestly successful IPO doesn't make a trend an improving $XBI and a focus on deals makes me wonder if the worst is over in biotech. I certainly hope so"
X Link @JohnCendpts 2025-10-13T11:45Z 70.7K followers, 4939 engagements
"Thumbs up to Kristina Burow and the other backers of Orbital as $BMY steps in with a $1.5B buyout. In vivo is where it's at right now. Ryan Cross featured Orbital in the 2023 Endpoints 11"
X Link @JohnCendpts 2025-10-10T13:33Z 70.7K followers, 2391 engagements
/creator/x::JohnCendpts